Corrigendum to “Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer” [Eur Urol 2023;83:313–17] (European Urology (2023) 83(4) (313–317), (S0302283822025386), (10.1016/j.eururo.2022.07.023))
Alberto Gil-Jimenez (Oncode Institute, Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Jeroen van Dorp (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Alberto Contreras-Sanz (University of British Columbia)
Kristan van der Vos (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Daniel J. Vis (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Linde Braaf (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Annegien Broeks (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Antonio Alcaraz (Universitat Politecnica de Catalunya)
Lodewyk F.A. Wessels (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, TU Delft - Electrical Engineering, Mathematics and Computer Science, Oncode Institute)
undefined More Authors (External organisation)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The authors regret that the following statement regarding author contributions was missed: Kristan van der Vos is currently a Scientific Editor for Cell Reports Medicine, which is published by Elsevier. Dr van der Vos was not involved in the peer-review process or editorial discussions about this manuscript. The authors would like to apologise for any inconvenience caused.